SYSTEMIC DELIVERY AND REGULATED EXPRESSION OF PARACRINE GENES FOR CARDIOVASCULAR DISEASES AND OTHER CONDITIONS

In alternative embodiments, the invention provides methods for treating, ameliorating or protecting (preventing) an individual or a patient against a disease, an infection or a condition responsive to an increased paracrine polypeptide level in vivo comprising: providing a paracrine polypeptide-encoding nucleic acid or gene operatively linked to a transcriptional regulatory sequence; or an expression vehicle, a vector, a recombinant virus, or equivalent, having contained therein a paracrine-encoding nucleic acid or gene, and the expression vehicle, vector, recombinant virus, or equivalent can express the paracrine-encoding nucleic acid or gene in a cell or in vivo; and administering or delivering the paracrine polypeptide-encoding nucleic acid or gene operatively linked to a transcriptional regulatory sequence, or the expression vehicle, vector, recombinant virus, or equivalent, to an individual or a patient in need thereof, thereby treating, ameliorating or protecting (preventing) the individual or patient against the disease, infection or condition responsive to an increased paracrine polypeptide level. 1. A method for treating type 1 diabetes in a subject comprising:administering to the subject a UCn2 gene, thereby treating the diabetes.2. The method of claim 1 , wherein the UCn2 gene is operably linked to a promoter.3. The method of claim 2 , wherein the UCn2 gene is in a vector.4. The method of claim 3 , wherein the vector is a viral vector.5. The method of claim 4 , wherein the vector is an adenoviral or an adeno-associated viral vector (AAV).6. The method of claim 5 , wherein the vector is selected from AAV8 or AAV9.7. The method of claim 1 , wherein the UCn2 gene is administered via intravenous (IV) delivery.8. The method of claim 2 , wherein the promoter is selected from a chicken beta-actin (CBA) claim 2 , thyroid hormone-binding globulin (TBG) claim 2 , or Rous Sarcoma Virus (RSV).9. The method of claim 1 , wherein the subject is a human.10. The method of ...

Cycle adenosine monophosphate-incompetent adenylyl cyclase and compositions and methods for treating heart failure and increasing cardiac function

The invention provides methods for treating, ameliorating or protecting (preventing) an individual or a patient having or at risk of having heart disease or heart failure, or decreased cardiac function, comprising: providing a cyclic adenosine monophosphate-incompetent (cAMP-incompetent) adenylyl cyclase type 6 (AC6) protein or polypeptide (also called “an AC6mut”), or an AC6mut-encoding nucleic acid or a gene operatively linked to a transcriptional regulatory sequence.

SYSTEMIC DELIVERY AND REGULATED EXPRESSION OF PARACRINE GENES FOR CARDIOVASCULAR DISEASES AND OTHER CONDITIONS

In alternative embodiments, the invention provides methods for treating, ameliorating or protecting (preventing) an individual or a patient against a disease, an infection or a condition responsive to an increased paracrine polypeptide level in vivo comprising: providing a paracrine polypeptide-encoding nucleic acid or gene operatively linked to a transcriptional regulatory sequence; or an expression vehicle, a vector, a recombinant virus, or equivalent, having contained therein a paracrine-encoding nucleic acid or gene, and the expression vehicle, vector, recombinant virus, or equivalent can express the paracrine-encoding nucleic acid or gene in a cell or in vivo; and administering or delivering the paracrine polypeptide-encoding nucleic acid or gene operatively linked to a transcriptional regulatory sequence, or the expression vehicle, vector, recombinant virus, or equivalent, to an individual or a patient in need thereof, thereby treating, ameliorating or protecting (preventing) the individual or patient against the disease, infection or condition responsive to an increased paracrine polypeptide level. 1. A method for treating , ameliorating , protecting or preventing an individual or a patient against a disease , an infection or a condition responsive to an increased or sustained peptide or paracrine polypeptide level in vivo comprising:(i) providing a paracrine polypeptide-encoding nucleic acid or gene operatively linked to a transcriptional regulatory sequence; or an expression vehicle, a vector, a recombinant virus, or equivalent, having contained therein a paracrine-encoding nucleic acid or gene, or a paracrine polypeptide-expressing nucleic acid, transcript or message, and the expression vehicle, vector, recombinant virus, or equivalent can express the paracrine-encoding nucleic acid, gene, transcript or message in a cell or in vivo; and(ii) administering or delivering the paracrine polypeptide-encoding nucleic acid, gene, transcript or message operatively ...

METHODS AND APPARATUS FOR PROGNOSTIC HEALTH MONITORING OF A TURBINE ENGINE

Methods, apparatus, systems, and articles of manufacture are disclosed to perform prognostic health monitoring of a turbine engine. An example apparatus includes a health quantifier calculator to execute a computer-generated model to generate first sensor data of a turbine engine, the first sensor data based on simulating a sensor monitoring the turbine engine using asset monitoring information, a parameter tracker to execute a tracking filter using the first sensor data and second sensor data to generate third sensor data corresponding to the turbine engine, the second sensor data based on obtaining sensor data from a sensor monitoring the turbine engine, the third sensor data based on comparing the first sensor data to the second sensor data, the health quantifier calculator to execute the computer-generated model using the third sensor data to generate an asset health quantifier of the turbine engine; and a report generator to generate a report including the asset health quantifier and a workscope recommendation based on the asset health quantifier when the asset health quantifier satisfies a threshold. 1. An apparatus comprising:a health quantifier calculator to execute a computer-generated model to generate first sensor data of a turbine engine, the first sensor data based on simulating a sensor monitoring the turbine engine;a parameter tracker to execute a tracking filter using the first sensor data and second sensor data to generate third sensor data corresponding to the turbine engine, the second sensor data based on obtaining sensor data from a sensor monitoring the turbine engine, the third sensor data based on comparing the first sensor data to the second sensor data;the health quantifier calculator to execute the computer-generated model using the third sensor data to generate an asset health quantifier of the turbine engine; anda recommendation generator to generate a workscope recommendation to improve an operation of the turbine engine when the asset ...

SYSTEMIC DELIVERY OF VIRUS VECTORS ENCODING UROCORTIN-2 AND RELATED GENES TO TREAT DIABETES-RELATED CARDIAC DYSFUNCTIONS AND CONGESTIVE HEART FAILURE

In alternative embodiments, provided are methods for treating, ameliorating or protecting (preventing) congestive heart failure (CHF) or a diabetes-related cardiac dysfunction, comprising: providing a urocortin 2-encoding and/or a urocortin 3-encoding nucleic acid, transcript or message, or gene, operatively linked to a transcriptional regulatory sequence, optionally contained in an expression vehicle or a vector such as an adeno-associated virus (AAV), e.g., an AAV8 serotype; and administering to an individual or a patient in need thereof, such as a type 2 diabetic (T2DM), e.g., by IV administration, thereby treating, ameliorating or protecting against (preventing) the T2DM and/or the diabetes-related cardiac dysfunction in the individual or patient. 1. A method for treating , ameliorating or protecting (preventing) , slowing the progress of , or reversing: a congestive heart failure (CHF); a type-2 diabetes mellitus (T2DM) and congestive heart failure (CHF); or a diabetes-related cardiac dysfunction in a type 2 diabetic (T2DM) , in an individual or a patient ,the method comprising:(a) (i) providing a urocortin 2 and/or a urocortin 3 polypeptide-encoding nucleic acid or gene operatively linked to a transcriptional regulatory sequence; or an expression vehicle, a vector, a recombinant virus, or equivalent, having contained therein a urocortin 2 and/or a urocortin 3-encoding nucleic acid or gene, or a urocortin 2 and/or a urocortin 3 polypeptide-expressing nucleic acid, transcript or message, and the expression vehicle, vector, recombinant virus, or equivalent can express the urocortin 2 and/or a urocortin 3-encoding nucleic acid, gene, transcript or message in a cell or in vivo; and(ii) administering or delivering the urocortin 2 and/or a urocortin 3 polypeptide-encoding nucleic acid, gene, transcript or message operatively linked to a transcriptional regulatory sequence, or the expression vehicle, vector, recombinant virus, or equivalent, to the cell, or an ...

SYSTEMIC DELIVERY OF VIRUS VECTORS ENCODING UROCORTIN-2 AND RELATED GENES TO TREAT DIABETES-RELATED CARDIAC DYSFUNCTIONS AND CONGESTIVE HEART FAILURE

In alternative embodiments, provided are methods for treating, ameliorating or protecting (preventing) congestive heart failure (CHF) or a diabetes-related cardiac dysfunction, comprising: providing a urocortin 2-encoding and/or a urocortin 3-encoding nucleic acid, transcript or message, or gene, operatively linked to a transcriptional regulatory sequence, optionally contained in an expression vehicle or a vector such as an adeno-associated virus (AAV), e.g., an AAV8 serotype; and administering to an individual or a patient in need thereof, such as a type 2 diabetic (T2DM), e.g., by IV administration, thereby treating, ameliorating or protecting against (preventing) the T2DM and/or the diabetes-related cardiac dysfunction in the individual or patient. 1. A method for treating , ameliorating or protecting or preventing , slowing the progress of , or reversing: a congestive heart failure (CHF); a type-2 diabetes mellitus (T2DM) and congestive heart failure (CHF); or a diabetes-related cardiac dysfunction in a type 2 diabetic (T2DM) , in an individual or a patient ,the method comprising:(a) (i) providing a urocortin 2 and/or a urocortin 3 polypeptide-encoding nucleic acid or gene operatively linked to a transcriptional regulatory sequence; or an expression vehicle, a vector, a recombinant virus, or equivalent, having contained therein a urocortin 2 and/or a urocortin 3-encoding nucleic acid or gene, or a urocortin 2 and/or a urocortin 3 polypeptide-expressing nucleic acid, transcript or message, and the expression vehicle, vector, recombinant virus, or equivalent can express the urocortin 2 and/or a urocortin 3-encoding nucleic acid, gene, transcript or message in a cell or in vivo; and(ii) administering or delivering the urocortin 2 and/or a urocortin 3 polypeptide-encoding nucleic acid, gene, transcript or message operatively linked to a transcriptional regulatory sequence, or the expression vehicle, vector, recombinant virus, or equivalent, to the cell, or an ...

SYSTEMS AND METHODS TO IDENTIFY INFLUENCERS IN A SOCIAL NETWORKING SYSTEM

Systems, methods, and non-transitory computer readable media are configured to determine one or more weights associated with connections between nodes representing users in a first graph. The one or more weights are adjusted based at least in part on an impact metric associated with a first user based on a second graph. An influence score associated with the first user is generated based on the one or more weights. 1. A computer-implemented method comprising:determining, by a computing system, one or more weights associated with connections between nodes representing users in a first graph;adjusting, by the computing system, the one or more weights based at least in part on an impact metric associated with a first user based on a second graph; andgenerating, by the computing system, an influence score associated with the first user based on the one or more weights.2. The computer-implemented method of claim 1 , wherein the one or more weights reflect a relationship between a first node associated with the first user and a second node associated with a second user.3. The computer-implemented method of claim 2 , wherein the one or more weights are based on at least one of a first parameter relating to a count of times that the second user took action in response to action taken by a first user claim 2 , a second parameter relating to a count of times that the second user received an invitation to take action from the first user claim 2 , and a third parameter relating to a coefficient value representing an affinity between the first user and the second user.4. The computer-implemented method of claim 1 , wherein the impact metric is determined from a component graph of the second graph.5. The computer-implemented method of claim 1 , wherein the impact metric is based on a count of other users who took downstream action in direct or indirect response to an action taken by the first user as reflected in an associated component graph.6. The computer-implemented method of ...

Methods and systems for camera calibration

An image capture method may include obtaining two or more sets of images. The two or more sets of images may include a first image captured by a first image capture device and a second image captured by a second image capture device. The method may also include determining, for a set of images, two or more pairs of points. Each of the two or more pairs of points may include a first point in the first image and a second point in the second image, and the first point and the second point may correspond to a same object. The method may also include determining a first rotation matrix based on the pairs of points in the two or more sets of images. The first rotation matrix may be associated with a relationship between positions of the first image capture device and the second image capture device.

COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF HEART FAILURE

In alternative embodiments, provided are compositions, including products of manufacture and kits, and methods, for treating a heart failure in a subject in need thereof comprising administering to the subject an isolated or recombinant nucleic acid, an isolated or recombinant or chimeric polypeptide, or an engineered cell, as provided herein, thereby treating the subject. In alternative embodiments, the administration reduces left ventricular (LV) hypertrophy, increases LV peak pressure development, reduced cAMP production and/or improves LV peak pressure decay in a pressure-overload in the subject. In alternative embodiments, provided are compositions and methods for: treating, ameliorating, or slowing the progress of, or protecting (preventing) an individual or a patient against heart failure; or, reducing LV hypertrophy, increasing LV peak pressure development, and/or improving LV peak pressure decay in a pressure-overload in an individual in need thereof. 1. An isolated or recombinant , or chimeric , polypeptide comprising a first peptide sequence and a second peptide sequence , wherein the first peptide sequence comprises or consists of a sequence as set forth in SEQ ID NO:1 and the second peptide sequence comprises or consists of a sequence as set forth in SEQ ID NO:2 , wherein the first peptide sequence and the second peptide sequence are operably linked.2. The isolated or recombinant claim 1 , or chimeric claim 1 , polypeptide of claim 1 , wherein the first peptide sequence and the second peptide sequence are operably linked via a fusion or a linker peptide claim 1 , or amino acid sequence.3. An isolated or recombinant nucleic acid or nucleic acid sequence encoding the isolated or recombinant claim 1 , or chimeric claim 1 , polypeptide of .4. An isolated or recombinant nucleic acid or nucleic acid sequence encoding the first peptide sequence of claim 1 , or an isolated or recombinant nucleic acid nucleic acid encoding an amino acid sequence as set forth in ...

Method for Delivering Sports Telemetry for a Curling Game

A method for delivering sports telemetry for a curling game provides players, coaches, and viewers with the detailed dynamics of a curling stone. The method is generalized to at least one computerized sports equipment in communication with at least one remote server. A sensing module of the sports equipment captures and sends an angular-motion measurement and a linear-motion measurement to the remote server. Further, a tracking module of the sports equipment sends a precise location reading to the remote server. The angular-motion measurement, the linear-motion measurement, and the precise location reading are compiled into a sports telemetry data. Subsequently, the sports telemetry data assess a plurality of summarization metrics which promotes game awareness and interest. Further, the sports telemetry data also generates at least one equipment motion animation of play-by-play breakdown of the game. Finally, an online view platform allows the general public to access the sports telemetry data.

METHOD OF TREATING TYPE I DIABETES USING AN AAV VECTOR ENCODING URACORTIN 2

In alternative embodiments, the invention provides methods for treating, ameliorating or protecting (preventing) an individual or a patient against a disease, an infection or a condition responsive to an increased paracrine polypeptide level in vivo comprising: providing a paracrine polypeptide-encoding nucleic acid or gene operatively linked to a transcriptional regulatory sequence; or an expression vehicle, a vector, a recombinant virus, or equivalent, having contained therein a paracrine-encoding nucleic acid or gene, and the expression vehicle, vector, recombinant virus, or equivalent can express the paracrine-encoding nucleic acid or gene in a cell or in vivo; and administering or delivering the paracrine polypeptide-encoding nucleic acid or gene operatively linked to a transcriptional regulatory sequence, or the expression vehicle, vector, recombinant virus, or equivalent, to an individual or a patient in need thereof, thereby treating, ameliorating or protecting (preventing) the individual or patient against the disease, infection or condition responsive to an increased paracrine polypeptide level. 1. A method for treating type 1 diabetes in a subject comprising:administering to the subject a UCn2 gene, thereby treating the diabetes.2. The method of claim 1 , wherein the UCn2 gene is operably linked to a promoter.3. The method of claim 2 , wherein the UCn2 gene is in a vector.4. The method of claim 3 , wherein the vector is a viral vector.5. The method of claim 4 , wherein the vector is an adenoviral or an adeno-associated viral vector (AAV).6. The method of claim 5 , wherein the vector is selected from AAV8 or AAV9.7. The method of claim 1 , wherein the UCn2 gene is administered via intravenous (IV) delivery.8. The method of claim 2 , wherein the promoter is selected from a chicken beta-actin (CBA) claim 2 , thyroid hormone-binding globulin (TBG) claim 2 , or Rous Sarcoma Virus (RSV).9. The method of claim 1 , wherein the subject is a human.10. The method of ...

Systemic administration and regulated expression of paracrine genes for cardiovascular diseases and other conditions

Un vector que comprende una secuencia de ácidos nucleicos que codifica una proteína o un péptido paracrino para su uso en un método para tratar, mejorar o proteger a un sujeto que padece una insuficiencia cardiaca congestiva que comprende proporcionar y administrar o suministrar el vector a una célula del sujeto, o a un sujeto en necesidad del mismo en el que la proteína o el péptido paracrino comprende una proteína o un péptido de la Urocortina-2 (UCn-2), y el vector es un virus adenoasociado (AAV). A vector comprising a nucleic acid sequence encoding a protein or a paracrine peptide for use in a method to treat, improve or protect a subject suffering from congestive heart failure comprising providing and administering or delivering the vector to a cell. of the subject, or a subject in need thereof in which the protein or paracrine peptide comprises a protein or a peptide of Urocortin-2 (UCn-2), and the vector is an adeno-associated virus (AAV).

Procedures for the resolution of the mixture of optical isomers, especially pinocembrin racemate

Un procedimiento para la resolución de una mezcla de isómeros ópticos de pinocembrina, en particular un racemato de pinocembrina, comprendiendo dicho procedimiento las siguientes etapas: (1) llevar a cabo una reacción de derivatización de una mezcla de isómeros ópticos de pinocembrina, que se ha sometido a una protección del grupo hidroxilo fenólico, con una amina primaria quiral para proporcionar una mezcla de diastereoisómeros, y llevar a cabo una separación de la mezcla de diastereoisómeros y opcionalmente llevar a cabo una purificación; y (2) desderivatizar los diastereoisómeros separados, y llevar a cabo una desprotección, y opcionalmente llevar a cabo una purificación, para obtener (R)-(+)-pinocembrina y/o (S)-(-)-pinocembrina, en el que dicha amina primaria quiral está representada por la siguiente fórmula general: amina primaria quiral en la que, R1 se selecciona de -H, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2 o -CH2OH; R2 se selecciona de fenilo, bencilo, o fenilo o bencilo con un sustituyente en un anillo aromático del mismo, -CH2OH-CH(OH)CH3, -CH(OH)C2H5, phCH(OH)- en el que el sustituyente se selecciona de -CH3, -CH2CH3, -CH2CH2CH3, -(CH2)3CH3, -CH(CH3)2, -NO2, -CF3, -F, -CI, -I, -OH, -OCH3, -OC2H5, -COOCH3, -COOC2H5, -CONH2, -CONHCH3, -CONHC2H5, -CON(CH3)2 o -CONHCH(CH3)2; R3 tiene la misma definición que la de R1 y R2 con la condición de que R3 no tenga la misma estructura que tiene R1 o R2 al mismo tiempo. A method for the resolution of a mixture of optical isomers of pinocembrina, in particular a racemate of pinocembrina, said procedure comprising the following steps: (1) carrying out a derivatization reaction of a mixture of optical isomers of pinocembrina, which has been subjected to a protection of the phenolic hydroxyl group, with a chiral primary amine to provide a mixture of diastereoisomers, and carry out a separation of the mixture of diastereoisomers and optionally carry out a purification; and (2) desderivatize the separated diastereoisomers, ...

Systemic delivery of virus vectors encoding urocortin-2 and related genes to treat diabetes-related cardiac dysfunctions and congestive heart failure

In alternative embodiments, provided are methods for treating, ameliorating or protecting (preventing) congestive heart failure (CHF) or a diabetes-related cardiac dysfunction, comprising: providing a urocortin 2-encoding and/or a urocortin 3-encoding nucleic acid, transcript or message, or gene, operatively linked to a transcriptional regulatory sequence, optionally contained in an expression vehicle or a vector such as an adeno-associated virus (AAV), e.g., an AAV8 serotype; and administering to an individual or a patient in need thereof, such as a type 2 diabetic (T2DM), e.g., by IV administration, thereby treating, ameliorating or protecting against (preventing) the T2DM and/or the diabetes-related cardiac dysfunction in the individual or patient.

Methods for resolution of the mixture of the optical isomers, especially the racemate of pinocembrin

Inclusion complexes of pinocembrin with cyclodextrin or its derivatives

Inclusion complexes of pinocembrin with cyclodextrin or its derivatives and their preparation are provided. The inclusion complexes can be used to make drugs.

Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions

Inclusion complexes of pinocembrin with cyclodextrin or its derivatives.

Se proporcionan complejos de inclusión de pinocembrina con ciclodextrina o sus derivados y su preparación; los complejos de inclusión se pueden usar para preparar fármacos.

Method for delivering sports telemetry for a curling game

A method for delivering sports telemetry for a curling game provides players, coaches, and viewers with the detailed dynamics of a curling stone. The method is generalized to at least one computerized sports equipment in communication with at least one remote server. A sensing module of the sports equipment captures and sends an angular-motion measurement and a linear-motion measurement to the remote server. Further, a tracking module of the sports equipment sends a precise location reading to the remote server. The angular-motion measurement, the linear-motion measurement, and the precise location reading are compiled into a sports telemetry data. Subsequently, the sports telemetry data assess a plurality of summarization metrics which promotes game awareness and interest. Further, the sports telemetry data also generates at least one equipment motion animation of play-by-play breakdown of the game. Finally, an online view platform allows the general public to access the sports telemetry data.

Inclusion complexes of pinocembrin with cyclodextrin or its derivatives

Method for delivering sports telemetry for a curling game

A method for delivering sports telemetry for a curling game provides players, coaches, and viewers with the detailed dynamics of a curling stone. The method is generalized to at least one computerized sports equipment in communication with at least one remote server. A sensing module of the sports equipment captures and sends an angular-motion measurement and a linear-motion measurement to the remote server. Further, a tracking module of the sports equipment sends a precise location reading to the remote server. The angular-motion measurement, the linear-motion measurement, and the precise location reading are compiled into a sports telemetry data. Subsequently, the sports telemetry data asses a plurality of summarization metrics which promotes game awareness and interest. Further, the sports telemetry data also generates at least one equipment motion animation of play-by-play breakdown of the game. Finally, an online view platform allows the general public to access the sports telemetry data.

Inclusion complexes of pinocembrin with cyclodextrin or its derivatives

Inclusion complexes of pinocembrin with cyclodextrin or its derivatives and their preparation are provided. The inclusion complexes can be used to make drugs.

Methods for resolution of the mixture of the optical isomers, especially the racemate of pinocembrin

Automatic brewing machine

一種自動沖泡機，包含一個機座，及至少一個自動沖泡設備，該自動沖泡設備包含一個送料裝置、一個開封裝置，及一個沖泡裝置。該送料裝置包括一個用於供數個包裝袋放置的輸送台、數個分別分隔所述包裝袋的分隔件，及一個帶動該等分隔件的輸送單元，該輸送台具有一個通槽。該開封裝置包括一個承接由該通槽掉落之包裝袋的載台、一個切割該包裝袋的切割單元，及一個用於將待沖泡物推擠出該包裝袋的推擠單元。該沖泡裝置用於將被擠出之待沖泡物加水沖泡成飲料。本發明能自動加水沖泡該包裝袋內之待沖泡物，使用上相當方便。

Use of derivatives of succinate esters for the treatment of dementia

The use of extract form Wangla (coeloglossum viride (L) Hartm. Var. Bracteatum (Willd.) Richter), succinate derivative esters, and a derivative and pharmaceutical acceptable salts thereof, for the manufacture of a pharmaceutical preparation for the treatment of dementia, particularly for the treatment of Alzheimer~ disease and Vascular dementia. Through Animal experiment, it has been demonstrated that, succinate derivative esters can improve learning and memory ability in dementia rats induced by scopolamine and cyclohexenyl imine; improve learning and memory ability in dementia rats induced by .beta.-amyloid; improve learning and memory ability in dementia rats induced by permanent ligation of bilateral carotid; and improve memory ability of normal animals. It has the advantage of high activity, low toxicity and no inhibition to cholinesterase.

Systemic delivery of virus vectors encoding urocortin-2 and related genes to treat diabetes-related cardiac dysfunction and congestive heart failure

In alternative embodiments, provided are methods for treating, ameliorating or protecting (preventing) congestive heart failure (CHF) or a diabetes-related cardiac dysfunction, comprising: providing a urocortin 2-encoding and/or a urocortin 3-encoding nucleic acid, transcript or message, or gene, operatively linked to a transcriptional regulatory sequence, optionally contained in an expression vehicle or a vector such as an adeno-associated virus (AAV), e.g., an AAV8 serotype; and administering to an individual or a patient in need thereof, such as a type 2 diabetic (T2DM), e.g., by IV administration, thereby treating, ameliorating or protecting against (preventing) the T2DM and/or the diabetes-related cardiac dysfunction in the individual or patient.

Methods and apparatus for prognostic health monitoring of a turbine engine

Methods, apparatus, systems, and articles of manufacture are disclosed to perform prognostic health monitoring of a turbine engine. An example apparatus includes a health quantifier calculator to execute a computer-generated model to generate first sensor data of a turbine engine, the first sensor data based on simulating a sensor monitoring the turbine engine using asset monitoring information, a parameter tracker to execute a tracking filter using the first sensor data and second sensor data to generate third sensor data corresponding to the turbine engine, the second sensor data based on obtaining sensor data from a sensor monitoring the turbine engine, the third sensor data based on comparing the first sensor data to the second sensor data, the health quantifier calculator to execute the computer-generated model using the third sensor data to generate an asset health quantifier of the turbine engine; and a report generator to generate a report including the asset health quantifier and a workscope recommendation based on the asset health quantifier when the asset health quantifier satisfies a threshold.

TWO TYPES OF PINOCEMBRINE CRYSTAL FORMS, ITS PREPARATION AND ITS USE TO MANUFACTURE PHARMACEUTICAL COMPOSITIONS

Dos formas cristalinas de pinocembrina de fórmula ): alfa y beta, su preparación y su uso para la fabricación de composiciones farmacéuticas. Existe una diferencia entre ellas en biodisponibilidad. Se usan para tratar y prevenir las enfermedades isquémicas cerebrales mediante la acción protectora de la unidad neurovascular, y aumentar el nivel de fármaco en sangre in vivo. ESPACIO PARA LA FÓRMULA Two crystalline forms of pinocembrina of formula): alpha and beta, its preparation and its use for the manufacture of pharmaceutical compositions. There is a difference between them in bioavailability. They are used to treat and prevent cerebral ischemic diseases through the protective action of the neurovascular unit, and increase the level of drug in blood in vivo. FORMULA SPACE

Dual recombinant gene therapy compositions and methods of use

The present invention relates to novel compositions and methods for the treatment of cardiovascular disease. More particularly, the invention relates to gene therapy compositions comprising at least two transgenes encoding angiogenic proteins or peptides. In one aspect the two transgenes are provided in a single gene delivery vector. Alternatively, the composition comprises at least two vectors, each vector comprising a transgene encoding a different angiogenic protein or peptide. The invention also relates to methods of treating cardiovascular disease using the gene therapy compositions; kits for gene delivery; and pharmaceutical compositions.

Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions

Transferrable electrode for printed electronics

A transferrable electrode arrangement comprising: a flexible release substrate having a release surface; and a transferrable electrode comprising at least one conductive layer located over the release surface of the release substrate comprising a solution-processed conductive layer, wherein the at least one conductive layer includes an interfacing conductive layer that interfaces with a receiving surface, and comprises a carbonaceous conductive layer or an organic conductive layer, and wherein the transferrable electrode is releasably attached to the release surface of the release substrate. FIGURE 1

A transferrable photovoltaic device

The invention provides a transferrable photovoltaic device arrangement for transferring a thin-film photovoltaic device to a bottom photovoltaic sub-cell to produce a tandem photovoltaic cell, the transferrable photovoltaic device arrangement comprising: a flexible release substrate; and a thin-film photovoltaic device comprising (i) a first transparent conductive layer located over the flexible release substrate and (ii) a photoactive layer located over the first transparent conductive layer, wherein the first transparent conductive layer is a solution-processed layer comprising at least one selected from a conductive polymer or polymer composite, an activatable adhesive, and an organic binder, and wherein the flexible release substrate is separable from the thin-film photovoltaic device after the thin-film photovoltaic device is adhered to the bottom photovoltaic sub-cell with a transparent conductive adhesive, thereby exposing the first transparent conductive layer at an outer conductive surface of the thin-film photovoltaic device.

Automatic door system and automatic door control method

An electromagnetic-activated latch device for saw blade guard of miter saw

Use of racemates of pinocembrin in preparing medicaments for treating stroke.

Barrier for use in drop test

一種供電控制電路

自動門系統及自動門控制方法

一種自動門系統包含一門主體、一驅動組件，及一電場偵測控制模組，該門主體根據一機械力的控制，變換於一打開狀態與一閉合狀態間，且包括一上邊框，該驅動組件連接於該門主體，且接收一控制信號，並根據該控制信號的指示產生該機械力，該電場偵測控制模組設置於該門主體的上邊框，且電連接該驅動組件，該電場偵測控制模組偵測自身與地間的K個電場的變化量，據以產生該控制信號，其中，K≧1。

Method of forming a perovskite film for an optoelectronic device

The invention provides a method of forming a perovskite film for an optoelectronic device, the method comprising: applying a perovskite precursor solution to at least one part of a hydrophilic region of a substrate, wherein the hydrophilic region is bounded by a hydrophobic boundary; allowing the perovskite precursor solution to spread over the hydrophilic region, wherein the perovskite precursor solution is retained within the hydrophilic region by at least a portion of the hydrophobic boundary; and drying the perovskite precursor solution to form a perovskite film on the hydrophilic region.

Method of forming a perovskite film for an optoelectronic device

The invention provides a method of forming a perovskite film for an optoelectronic device, the method comprising: applying a perovskite precursor solution to at least one part of a hydrophilic region of a substrate, wherein the hydrophilic region is bounded by a hydrophobic boundary; allowing the perovskite precursor solution to spread over the hydrophilic region, wherein the perovskite precursor solution is retained within the hydrophilic region by at least a portion of the hydrophobic boundary; and drying the perovskite precursor solution to form a perovskite film on the hydrophilic region.

Method of forming a perovskite film for an optoelectronic device

Use of racemates of pinocembrin in preparing medicaments for treating stroke

Non-flexible adjustable one-piece underwear

Methods and systems for camera calibration

An image capture method may include obtaining two or more sets of images. The two or more sets of images may include a first image captured by a first image capture device and a second image captured by a second image capture device. The method may also include determining, for a set of images, two or more pairs of points. Each of the two or more pairs of points may include a first point in the first image and a second point in the second image, and the first point and the second point may correspond to a same object. The method may also include determining a first rotation matrix based on the pairs of points in the two or more sets of images. The first rotation matrix may be associated with a relationship between positions of the first image capture device and the second image capture device.

Inclusion complexes of pinocembrin with cyclodextrin or its derivatives

INCLUSION COMPLEXES OF PINOCEMBRIN WITH CYCLODEXTRIN OR ITS DERIVATIVES INCLUSION COMPLEXES OF PINOCEMBRIN WITH CYCLODEXTRIN OR ITS DERIVATIVES AND THEIR PREPARATION ARE PROVIDED. THE INCLUSION COMPLEXES CAN BE USED TO MAKE DRUGS.

Non-elastic union suit

Methods and apparatus for prognostic health monitoring of a turbine engine

Method of forming a perovskite film for an optoelectronic device

The invention provides a method of forming a perovskite film for an optoelectronic device, the method comprising: applying a perovskite precursor solution to at least one part of a hydrophilic region of a substrate, wherein the hydrophilic region is bounded by a hydrophobic boundary; allowing the perovskite precursor solution to spread over the hydrophilic region, wherein the perovskite precursor solution is retained within the hydrophilic region by at least a portion of the hydrophobic boundary; and drying the perovskite precursor solution to form a perovskite film on the hydrophilic region.

Non-flexible adjustable one-piece underwear

Concealed safety locking device for eye goggles used in a cutting machine

Customer address multi-mode input and 5-digit ZIP code converting tool

Compositions and methods for the treatment or prevention of heart failure

In alternative embodiments, provided are compositions, including products of manufacture and kits, and methods, for treating a heart failure in a subject in need thereof comprising administering to the subject an isolated or recombinant nucleic acid, an isolated or recombinant or chimeric polypeptide, or an engineered cell, as provided herein, thereby treating the subject. In alternative embodiments, the administration reduces left ventricular (LV) hypertrophy, increases LV peak pressure development, reduced cAMP production and/or improves LV peak pressure decay in a pressure-overload in the subject. In alternative embodiments, provided are compositions and methods for: treating, ameliorating, or slowing the progress of, or protecting (preventing) an individual or a patient against heart failure; or, reducing LV hypertrophy, increasing LV peak pressure development, and/or improving LV peak pressure decay in a pressure-overload in an individual in need thereof.

Random angle positioning device of cutting machine

Cycle adenosine monophosphate-incompetent adenylyl cyclase and compositions and methods for treating heart failure and increasing cardiac function

Cycle adenosine monophosphate-incompetent adenylyl cyclase and compositions and methods for treating heart failure and increasing cardiac function

CYCLIC ADENOSIN MONONPHOSPHATE INSUFFICIENT ADENYLYL CYCLE AND COMPOSITIONS AND METHODS FOR TREATING HEART WEIGHT AND INCREASING HEART FUNCTION

Cycle adenosine monophosphate-incompetent adenylyl cyclase and compositions and methods for treating heart failure and increasing cardiac function

The invention provides methods for treating, ameliorating or protecting (preventing) an individual or a patient having or at risk of having heart disease or heart failure, or decreased cardiac function, comprising: providing a cyclic adenosine monophosphate-incompetent (cAMP-incompetent) adenylyl cyclase type 6 (AC6) protein or polypeptide (also called "an AC6mut"), or an AC6mut -encoding nucleic acid or a gene operatively linked to a transcriptional regulatory sequence.

HeLa-C3 Apoptosis Inducer from Garcinia paucinervis

A novel compound isolated from the plant Garcinia paucinervis . The compound's structure is as follows: The compound possesses a potent ability to activate caspase-3 in HeLa-C3 cells within 72 h at a low concentration of 25 μM. The IC 50 on HeLa cells for this compound was measured to be below 10 μM, indicating a strong HeLa cell growth inhibitory effect.

Novel Polyisoprenylated Benzophenone Derivatives from Garcinia paucinervis

Novel polyisoprenylated benzophenone derivatives isolated from the plant Garcinia paucinervis . Among these new compounds, paucinones A-C (Compounds 1-3) contains an unexpected cyclohexane-spiro-tetrahydrofuran moiety. A 1-methylene-3,3-dimethylcyclohexane group never reported before was found in the structure of paucinone D (Compound 4). Structures of these compounds were elucidated with spectroscopic evidence. The relative stereochemistry of 1-4 was determined by NOESY correlations. These compounds a potent ability to activate caspase-3 in HeLa-C3 cells within 72 hours at a low concentration and significant cytotoxicity against HeLa-C3 cells.

Transferrable electrode for printed electronics

A transferrable electrode arrangement comprising: a flexible release substrate having a release surface; and a transferrable electrode comprising at least one conductive layer located over the release surface of the release substrate comprising a solution-processed conductive layer, wherein the at least one conductive layer includes an interfacing conductive layer that interfaces with a receiving surface, and comprises a carbonaceous conductive layer or an organic conductive layer, and wherein the transferrable electrode is releasably attached to the release surface of the release substrate. FIGURE 1

兼具芳香及提高曬乾效果之衣架結構

Warm toilet mat

掛網延伸架

固定引流袋之腰包結構

Procede d'amelioration de l'efficacite de la transmission de canal dans un reseau sans fil

固定建築鷹架之壁拉桿

一種控制裝置

本發明公開了一種控制裝置，用於控制硬碟與電子裝置之間的連接，所述電子裝置包括用於連接硬碟的硬碟連接器，所述控制裝置包括：一檢測電路，與所述硬碟連接器的接地引腳連接，用於檢測硬碟的連接狀態，並產生檢測信號；一中央處理器，與所述檢測電路連接，用於接收所述檢測信號，並根據所述檢測信號發送控制信號；以及至少一電源控制電路，與所述中央處理器連接，並與所述硬碟連接器連接，用於接收所述控制信號，並根據所述控制信號控制所述硬碟供電。

Inclusion complexes of pinocembrin with cyclodextrin or its derivatives

Inclusion complexes of pinocembrin with cyclodextrin or its derivatives and their preparation are provided. The inclusion complexes can be used to make drugs.